In contrast, the signal proceeds normally or with greater strength (because of compensatory hyperinsulinemia of various degrees) along the Shc-Ras-MAP kinase pathway, eliciting greater responses ...

found in up to 85% of cancers driven by RAS alterations. Developed in-house, BAY3498264 addresses the unmet medical need of improving efficacy of treatment targeting the mitogen-activated protein ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...

OS is an important factor that leads to DNA damage and stimulates carcinogenesis through dysregulation of signaling pathways that are important for tumor survival and metastasis. Studies have ...

Historically, scientists in the division were the first to make the ground-breaking discovery of the mechanism by which the RAS gene – one of the ... through activation of the ERK-MAP kinase cell ...

IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Non-Small Cell Lung Cancer.

Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Non-Small Cell Lung Cancer.

Cell competition in epithelial tissue eliminates transformed cells expressing activated oncoproteins to maintain epithelial homeostasis. Although the process is now understood to be of mechanochemical ...